Herein, we evaluated the relationship of irAEs with tumor response and survival in patients with unresectable advanced or recurrent ESCC treated with second- or later-line nivolumab, an anti-PD-1 antibody, monotherapy. This evidence concerns the gene PDCD1 and neoplasm.